X-136206434-T-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_001159702.3(FHL1):c.2T>C(p.Met1?) variant causes a start lost change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Genomes: not found (cov: 24)
Consequence
FHL1
NM_001159702.3 start_lost
NM_001159702.3 start_lost
Scores
6
6
2
Clinical Significance
Conservation
PhyloP100: 6.26
Genes affected
FHL1 (HGNC:3702): (four and a half LIM domains 1) This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. Expression of these family members occurs in a cell- and tissue-specific mode and these proteins are involved in many cellular processes. Mutations in this gene have been found in patients with Emery-Dreifuss muscular dystrophy. Multiple alternately spliced transcript variants which encode different protein isoforms have been described.[provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant X-136206434-T-C is Pathogenic according to our data. Variant chrX-136206434-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 2861396.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FHL1 | NM_001159702.3 | c.2T>C | p.Met1? | start_lost | 3/8 | ENST00000394155.8 | |
FHL1 | NM_001159699.2 | c.50T>C | p.Met17Thr | missense_variant | 2/6 | ENST00000370683.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FHL1 | ENST00000394155.8 | c.2T>C | p.Met1? | start_lost | 3/8 | 5 | NM_001159702.3 | ||
FHL1 | ENST00000370683.6 | c.50T>C | p.Met17Thr | missense_variant | 2/6 | 1 | NM_001159699.2 | P1 |
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD3 genomes
Cov.:
24
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 24
GnomAD4 genome
Cov.:
24
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
X-linked myopathy with postural muscle atrophy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 01, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant has not been reported in the literature in individuals affected with FHL1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects the initiator methionine of the FHL1 mRNA. There are no downstream in-frame methionine residues; therefore, it is expected to result in an absent or disrupted protein product. Loss-of-function variants in FHL1 are known to be pathogenic (PMID: 18179888, 19687455, 19716112, 22523091, 24114807). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;T;.;T;.;T;T;T;.;.;T;T;T;.;T;T;.;.;T;.;T;T;.;.;.;T;T;.
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;.;D;D;D;D;D;D;.;D;.;.;.;D;D;.;D;D;D;D;.;.;D;D;D;D;.
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
D;D;D;D;D;D;D;D;D
PROVEAN
Uncertain
.;D;D;.;.;D;D;.;.;.;.;D;.;D;.;D;D;D;D;.;D;D;.;D;D;D;D;.
REVEL
Uncertain
Sift
Uncertain
.;D;D;.;.;D;D;.;.;.;.;D;.;D;.;D;D;D;D;.;D;D;.;D;D;D;D;.
Sift4G
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;.;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
Polyphen
1.0, 1.0
.;D;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;D;.;.;.;D;.;.
Vest4
MutPred
Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);.;.;.;Gain of catalytic residue at M1 (P = 0.0439);Gain of catalytic residue at M1 (P = 0.0439);
MVP
ClinPred
D
GERP RS
Varity_R
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.